# Preclinical Therapeutics Core

> **NIH NIH P01** · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · 2023 · $232,012

## Abstract

CORE B PROJECT SUMMARY
Core B Preclinical Therapeutics will provide purified antibodies for conjugation and use in Projects 1 and 2 to
generate novel caveolae-targeting imaging and therapeutic agents. The Core will also provide analytical
services to ensure quality control of reagents that will be used for preclinical animal testing. Antibodies
generated in Core B will be conjugated to radionuclides in Core D for use in Project 1. Antibodies will be
provided to Project 2 for conjugation to various chemotherapies, and testing in preclinical metastatic models of
disease. Reagents developed in Projects 1 and 2 will be rigorously evaluated for quality control using analytical
services provided by Core B prior to use in any animal studies. Core B will also provide support services and
guidance for the cGMP production of the humanized antibody and therapeutic agents destined for clinical trials,
including scale-up, process development, validation, batch testing, compliance, and providing technical
expertise as needed to ensure successful technology transfer and quality manufacturing of finished goods.

## Key facts

- **NIH application ID:** 10655412
- **Project number:** 5P01CA221775-05
- **Recipient organization:** PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED
- **Principal Investigator:** Michael David Levin
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $232,012
- **Award type:** 5
- **Project period:** 2019-07-08 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10655412

## Citation

> US National Institutes of Health, RePORTER application 10655412, Preclinical Therapeutics Core (5P01CA221775-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10655412. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*